SABS FY2030 EPS Boosted by Brookline Capital Markets

Posted by Stanley Muller on Aug 7th, 2026

SAB Biotherapeutics, Inc. (NASDAQ:SABS – Free Report) – Analysts at Brookline Capital Markets upped their FY2030 earnings estimates for shares of SAB Biotherapeutics in a research note issued on Thursday, August 6th. Brookline Capital Markets analyst K. Raja now forecasts that the company will post earnings of $1.38 per share for the year, up from their previous forecast of $1.17. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($1.19) per share.

SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.28) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.28).

Other analysts have also recently issued research reports about the company. Leerink Partners lifted their price target on SAB Biotherapeutics from $7.00 to $12.00 and gave the stock an “outperform” rating in a research report on Monday, June 15th. Wall Street Zen lowered SAB Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, August 2nd. Zacks Research raised SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th. Chardan Capital raised their price objective on SAB Biotherapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Wednesday, June 17th. Finally, Barclays started coverage on SAB Biotherapeutics in a report on Wednesday, June 24th. They set an “overweight” rating and a $13.00 target price for the company. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, SAB Biotherapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

Get Our Latest Stock Report on SABS

SAB Biotherapeutics Price Performance

Shares of SABS opened at $3.85 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.45 and a quick ratio of 11.45. The company’s fifty day moving average price is $3.68 and its 200-day moving average price is $3.83. SAB Biotherapeutics has a 1-year low of $1.85 and a 1-year high of $5.15. The firm has a market capitalization of $294.37 million, a PE ratio of -1.82 and a beta of 0.53.

Institutional Investors Weigh In On SAB Biotherapeutics

Several hedge funds have recently added to or reduced their stakes in SABS. PNC Financial Services Group Inc. acquired a new stake in SAB Biotherapeutics during the 1st quarter worth about $29,000. ADAR1 Capital Management LLC acquired a new position in shares of SAB Biotherapeutics in the 3rd quarter valued at about $30,000. Dimensional Fund Advisors LP purchased a new stake in shares of SAB Biotherapeutics in the third quarter worth about $32,000. State of Wyoming purchased a new stake in shares of SAB Biotherapeutics in the fourth quarter worth about $34,000. Finally, Virtu Financial LLC acquired a new stake in SAB Biotherapeutics during the third quarter worth about $40,000. 7.82% of the stock is owned by hedge funds and other institutional investors.

SAB Biotherapeutics Company Profile

(Get Free Report)

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.